Aura Biosciences, Inc. (AURA)
NASDAQ: AURA · Real-Time Price · USD
6.96
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
6.96
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Aura Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 22.49 | 22.81 | 19.76 | 18.06 | 10.09 | |
| Research & Development | 90.3 | 73.3 | 65.23 | 42.24 | 25.16 | |
| Operating Expenses | 112.79 | 96.12 | 84.99 | 60.3 | 35.25 | |
| Operating Income | -112.79 | -96.12 | -84.99 | -60.3 | -35.25 | |
| Interest & Investment Income | 6.63 | 9.43 | 8.59 | 1.86 | 0.01 | |
| Other Non Operating Income (Expenses) | 0.08 | -0.12 | -0.08 | -0.01 | -0.01 | |
| EBT Excluding Unusual Items | -106.08 | -86.81 | -76.48 | -58.45 | -35.25 | |
| Gain (Loss) on Sale of Assets | - | - | 0.21 | -0.32 | -0 | |
| Pretax Income | -106.08 | -86.81 | -76.27 | -58.76 | -35.25 | |
| Income Tax Expense | 0.11 | 0.11 | 0.14 | - | - | |
| Net Income | -106.19 | -86.92 | -76.41 | -58.76 | -35.25 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | 10.94 | |
| Net Income to Common | -106.19 | -86.92 | -76.41 | -58.76 | -46.19 | |
| Shares Outstanding (Basic) | 60 | 50 | 40 | 30 | 5 | |
| Shares Outstanding (Diluted) | 60 | 50 | 40 | 30 | 5 | |
| Shares Change (YoY) | 21.52% | 25.32% | 32.34% | 480.18% | 1305.21% | |
| EPS (Basic) | -1.76 | -1.75 | -1.93 | -1.96 | -8.95 | |
| EPS (Diluted) | -1.76 | -1.75 | -1.93 | -1.96 | -8.95 | |
| Free Cash Flow | -85.19 | -81.06 | -64.56 | -55.7 | -34.54 | |
| Free Cash Flow Per Share | -1.41 | -1.63 | -1.63 | -1.86 | -6.69 | |
| EBITDA | -111.66 | -94.89 | -83.7 | -59.12 | -34.42 | |
| D&A For EBITDA | 1.13 | 1.22 | 1.3 | 1.18 | 0.83 | |
| EBIT | -112.79 | -96.12 | -84.99 | -60.3 | -35.25 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.